Viatris Inc Reports Q3 2026 Financial Results & Raises Full-Year Guidance

Executive Summary

On November 5, 2026, Viatris Inc. (NASDAQ: VTRS) filed a Form 8-K under Items 2.02 and 8.01, announcing its financial results for the third quarter ended September 30, 2026, and furnishing Exhibit 99.1 (earnings press release).

Key Financial Highlights (Q3 2026)

• Revenues: Total revenues reached $3.75 billion, flat compared to $3.76 billion in Q3 2025.
• Sales by Geography: Developed Markets generated $2.22 billion (-2% reported), Greater China grew 14% reported to $702.6 million, Emerging Markets delivered $529.1 million (-7%), and JANZ posted $287.1 million (-6%).
• Sales by Product Category: Brands net sales were $2.46 billion (+1%), while Generics net sales were $1.27 billion (-3%).
• Profitability:
  • GAAP Gross Margin was 38.4% (up from 36.5% in Q3 2025); Adjusted Gross Margin reached 58.0%.
  • GAAP Net Loss was $(325.3) million ($(0.28) per share), compared to a loss of $(128.2) million in the prior-year period.
  • Adjusted Net Earnings grew 5% to $821.4 million ($0.71 Adjusted EPS).
  • Adjusted EBITDA rose 4% year-over-year to $1.196 billion.
• Cash Flow & Capital Allocation:
  • Net cash provided by operating activities was $899.4 million, with Free Cash Flow of $813.7 million (+24% YoY).
  • Returned approximately $717 million of capital to shareholders year-to-date, including share buybacks.

Business & Pipeline Updates

• Regulatory approval received for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan.
• Raised full-year 2026 financial guidance midpoints across all key operational metrics.
• Continued execution on innovative medicines strategy with the planned acquisition of Pacira BioSciences, anticipated to close by late November 2026.

Insider Trading Assessment

This Form 8-K is an operational and financial results disclosure and does not report insider equity transactions.